Key Takeaways
- Novo Nordisk’s amycretin injections resulted in an average weight loss of 22% over 36 weeks.
- The positive results triggered an 11% increase in the company’s stock price during premarket trading.
- Further details on safety and potential long-term efficacy of amycretin are yet to be disclosed.
Novo Nordisk has announced promising results from its phase 1b/2a study on amycretin, a novel treatment aimed at tackling obesity. The study involved 125 participants who were either overweight or classified as obese. Participants receiving weekly injections of amycretin lost an average of 22% of their body weight after 36 weeks, showcasing significant efficacy when compared to a placebo group. Specifically, those administered 1.25 mg of the drug experienced a 9.7% weight loss after 20 weeks, while those on higher doses—5 mg and 20 mg—lost 16.2% and 22%, respectively, at the 28-week and 36-week marks. These findings are based on an analysis that only included patients who adhered strictly to their treatment regimen.
The stock market reacted favorably to the announcement, with Novo’s share price rising by 11%, approaching $90 during premarket trading. This increase follows recent challenges faced by the company, particularly after Eli Lilly’s Zepbound demonstrated superior weight loss results in a head-to-head clinical trial and subsequent weight loss improvements over time. Despite recent setbacks involving the efficacy of high-dose Wegovy and CagriSema, amycretin’s results have provided a much-needed boost for the drugmaker.
However, investors remain cautious as the provided data lacks depth. Novo Nordisk has not disclosed whether weight loss effects may plateau after 36 weeks or if continued treatment could yield further improvements, which continues to be a focal point of inquiry for market analysts. In comparison, Zepbound’s results showed an increase in weight loss from 20.9% after 36 weeks to 25.8% after 88 weeks, raising the question of amycretin’s long-term effectiveness.
As for safety, Novo stated that the adverse events reported were largely mild to moderate, aligning with the profiles typical of incretin therapies. The common issues noted were gastrointestinal in nature, but specifics regarding other side effects or long-term tolerability have yet to be revealed. The promising efficacy shown in the study has encouraged Novo to advance amycretin towards further clinical development, although details on the upcoming phases have not been fully outlined.
In parallel to the investigations involving subcutaneous amycretin, Novo is also developing an oral version of the treatment. Last year’s phase 1 data for the oral formulation indicated that patients could achieve a weight loss of 13.1% after taking the drug daily for 12 weeks.
As Novo Nordisk navigates the subsequent steps for amycretin, the focus will be on expanding understanding of its efficacy and safety profile, ensuring its competitiveness in an evolving market for obesity treatments.
The content above is a summary. For more details, see the source article.